Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Advances in the Pre-clinical Evaluation of Hepatitis B Therapies

Published: Tuesday, September 02, 2014
Last Updated: Tuesday, September 02, 2014
Bookmark and Share
Imperial College London to present first public HBV Data from CN Bio in vitro liver model.

CN Bio Innovations Ltd has announced that data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be the subject of oral and poster presentations at three international meetings this Fall, including:

•         The 2014 International Meeting on Hepatitis B in Los Angeles, USA (3-6 September, 2014)
•         The Viral Hepatitis Congress 2014 in Frankfurt, Germany (9-11 October, 2014)
•         The Liver Meeting® 2014*, Boston USA (7-11 November, 2014). CN Bio will also host an Investigator Meeting** on Monday 10th November, which is an invitation-only event for attendees of The Liver Meeting® 2014.

First public presentations

Dr Marcus Dorner, Lead Principle Investigator for the study, commented: “It’s an honour to be invited to present our data at these prestigious meetings, where we’ll show how CN Bio’s Hepatitis B liver disease model accurately recapitulates the full life-cycle of HBV without the need for interventions such as the solvent permeabilization of cells. This makes it a uniquely powerful tool for developing and testing new HBV treatments.”

A breakthrough in HBV research

Dr Emma Sceats, COO at CN Bio said, “The work completed through this collaboration with Dr Dorner and his team represents an important breakthrough. The absence of suitable in vitro and animal models of Hepatitis B limits our ability to effectively analyse the biology and pathology of the disease, making the development of effective drugs very challenging. Hopefully, using new, advanced technologies such as these, novel therapies will reach market more quickly, helping to treat the more than 300 million patients worldwide infected with Hepatitis B.”

*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases
**This event is not an official function/event of the American Association for the Study of Liver Diseases

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos